Coats, the world’s leading industrial thread company, is partnering with HeiQ, a Swiss technology company, to incorporate HeiQ Viroblock technology into its engineered yarns.
The agreement also gives Coats exclusive global access to the technology for use in sewing threads. HeiQ Viroblock is among the first textile technologies in the world to be proven effective in laboratory testing against SARS-CoV-2, the virus from the coronavirus family that causes COVID-19. It has been shown to be 99.99% effective in 30 minutes in tests conducted with the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia.
The Coats Innovation Hub – America in North Carolina, US, is adapting HeiQ Viroblock technology to create a new range of threads and engineered yarns suitable for application across a wide range of end-use products. Non-toxic and hypoallergenic, HeiQ Viroblock merges microsilver technology to attract virus particles which then combine with vesicle technology to break down the viral membrane within seconds. The microsilver technology uses recycled silver to enhance its sustainable offering, while the vesicle technology is bio-based.
Ronan Cox, President, Performance Materials, Coats, said: ‘The combination of HeiQ Viroblock technology with our specialist expertise in threads and yarns creates a unique and powerful textile solution for the challenges we see today. The innovation infrastructure we have built at Coats continues to deliver exciting industry changing concepts that have real large scale commercial potential.’
Coats prides itself on its innovation which has become a key focus following the development of its three Innovation Hubs in China, Turkey and the US. These centres provide the opportunity for technical experts from Coats to work alongside industry partners and customers in real time on dedicated machinery to develop ground-breaking solutions for all the industries Coats supplies.
